3-Cl-PCP
3-chlorophencyclidine
1Provenance card
the boundary, as counts
Sources
2811 with DOI
1 strong · 19 moderate · 8 weak
Compilations
12026-05-07T19:15:55.788Z
pipeline-v5 · prompt hash not recorded — run predates 2026-09
Decisions
34last ruled 2026-06-04
0 awaiting a ruling
Issued documents
42026-10-19T20:29:32.251Z
notice · info card · emergency
Searches
226 with no results
queries and counts on the build
Claims checked
7354 supported
54 supported · 19 not
Correspondence
0received
consent field ships in Phase 4
Edges
243
derivations recorded for this entity
Complete over 28 sources, 1 compilation, and 34 decisions.Not here: the private journal (never).Working material — drafts, discards, unsupported claims — is listed below and readable on the working page.Cite: psychedex.org/substances/3-cl-pcp/archive
Timeline
what happened, newest first — claims, searches and artifacts stay inside Build
- 2026-10-19issueIssued info_card
- 2026-09-07srcQualitative and quantitative in silico toxicity profiling of 'angel dust': phencyclidine (PCP) analogues as new psychoactive substances (3-HO-PCP, 3-MeO-PCP, 4-MeO-PCP, 3-HO-PCE, 3-MeO-PCE, 4-MeO-PCE)
- 2026-09-07srcADME profile of phencyclidine (PCP) analogues: emerging dissociative hallucinogens 3-MeO-PCP (CAS: 72242-03-6) and 4-MeO-PCP — a multi-in silico approach
- 2026-09-07srcRhabdomyolysis and Acute Kidney Injury after Use of 3-Methyl-PCP: A Case Report
- 2026-09-07srcA non-fatal intoxication and seven deaths involving the dissociative drug 3-MeO-PCP
- 2026-09-07srcNovel psychoactive substance intoxication resulting in attempted murder
- 2026-09-07srcThe neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia.
- 2026-09-07srcOverdoses and deaths related to the use of ketamine and its analogues: a systematic review
- 2026-09-07srcMetabolism and metabolomics of ketamine: a toxicological approach
- 2026-09-07srcMethoxetamine, a novel psychoactive substance with serious adverse pharmacological effects: a review of case reports and preclinical findings
- 2026-09-07srcPhencyclidine-Like Abuse Liability and Psychosis-Like Neurocognitive Effects of Novel Arylcyclohexylamine Drugs of Abuse in Rodents
- 2026-09-07srcThe Evolving Challenge of New Psychoactive Substances: Understanding the Risks and Behavioral Effects of Novel Analogs of Dissociative Anesthetics
- 2026-09-07srcNMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D2 and serotonin 5-HT2 receptors - implications for models of schizophrenia
- 2026-09-07srcBioactivation of phencyclidine in rat and human liver microsomes and recombinant P450 2B enzymes: evidence for the formation of a novel quinone methide intermediate
- 2026-09-07srcPhencyclidine intoxication and adverse effects: a clinical and pharmacological review of an illicit drug
- 2026-09-07srcSigma binding sites in the brain; an emerging concept for multiple sites and their relevance for psychiatric disorders
- 2026-09-07srcDifferent modulation of the binding to two phencyclidine (PCP) receptor subtypes: effects of N-methyl-D-aspartate agonists and antagonists
- 2026-09-07srcReceptor mediation of the discriminative stimulus properties of phencyclidine and sigma-opioid agonists
- 2026-09-07srcContinuous intravenous infusion of phencyclidine in unrestrained rats results in the rapid induction of tolerance and physical dependence
- 2026-09-07srcThe effects of acute and chronic phencyclidine on schedule-controlled behavior in the squirrel monkey
- 2026-09-07srcEffects of SKF-10047 in the phencyclidine-dependent rat: evidence for common receptor mechanisms
- 2026-09-07srcPhencyclidine disposition in humans after small doses of radiolabeled drug.
- 2026-09-07srcUrine pH and phencyclidine excretion
- 2026-09-07srcModulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders
- 2026-09-07src3-Cl-PCP Toxicology Report (CFSRE / Slovenian Police)
- 2026-09-07src3-Cl-PCP - PsychonautWiki
- 2026-09-07srcPhencyclidine-type substances - UNODC Laboratory and Scientific Service
- 2026-09-07src3-Cl-PCP: Analyzing This Rare Dissociative Psychedelic
- 2026-09-07srcSchedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I (Final Rule)
- 2026-09-04issueIssued emergency
- 2026-09-04issueIssued info_card
- 2026-09-04issueIssued notice
- 2026-06-04proposal32 value proposals approved togetherone review action inferred from a shared reviewer and instant — the graph records one activity per proposal
- 2026-06-04publicationPublication — backfill
- 2026-05-07revisionRevision 1
- 2026-05-07absenceSearched Federal Register for "3-Cl-PCP scheduling DEA" — no results
- 2026-05-07absenceSearched PubMed for "3-Cl-PCP arylcyclohexylamine dissociative binding affinity NMDA" — no results
- 2026-05-07absenceSearched ClinicalTrials.gov for "3-chloro phencyclidine dissociative arylcyclohexylamine" — no results
- 2026-05-07absenceSearched PubMed for "phencyclidine ring-substituted analogs structure activity relationship CNS" — no results
- 2026-05-07absenceSearched PubChem for "3-Cl-PCP" — no results
- 2026-05-07absenceSearched OpenAlex for "3-chlorophencyclidine arylcyclohexylamine NMDA receptor" — no results
- 2026-05-07genGeneration — pipeline-v5 · with 3 morepipeline-v5
- 2026-05-07rungeneration run
The same entries, as forms: six forms.